FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3016250087> ?p ?o ?g. }

• W3016250087 endingPage "2020" @default.
• W3016250087 startingPage "2008" @default.
• W3016250087 abstract "Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (<65, ≥65 to <75 and ≥75 years).Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods (stratified by study) assessed OS, progression-free survival (PFS), time to progression (TTP) and patient-reported outcomes (Functional Hepatobiliary System Index-8 [FHSI-8] score).A total of 542 patients (<65 years: n = 302; ≥65 to <75 years: n = 160; ≥75 years: n = 80) showed similar baseline characteristics between ramucirumab and placebo. Older subgroups had higher hepatitis C and steatohepatitis incidences, and lower AFP levels, than the <65 years subgroup. Ramucirumab prolonged OS in patients <65 years (hazard ratio [HR], 0.753; 95% CI 0.581-0.975), ≥65 to <75 years (0.602; 0.419-0.866) and ≥75 years (0.709; 0.420-1.199), PFS and TTP irrespective of age. Ramucirumab showed similar overall safety profiles across subgroups, with a consistent median relative dose intensity ≥97.8%. A trend towards a delay in symptom deterioration in FHSI-8 with ramucirumab was observed in all subgroups.In this post-hoc analysis, ramucirumab showed a survival benefit across age subgroups with a tolerable safety profile, supporting its use in advanced HCC with elevated AFP, irrespective of age, including ≥75 years." @default.
• W3016250087 created "2020-04-17" @default.
• W3016250087 creator A5006848714 @default.
• W3016250087 creator A5008862276 @default.
• W3016250087 creator A5009242828 @default.
• W3016250087 creator A5020551368 @default.
• W3016250087 creator A5022288769 @default.
• W3016250087 creator A5022484327 @default.
• W3016250087 creator A5025634287 @default.
• W3016250087 creator A5027983969 @default.
• W3016250087 creator A5032900701 @default.
• W3016250087 creator A5033735284 @default.
• W3016250087 creator A5039119608 @default.
• W3016250087 creator A5041690302 @default.
• W3016250087 creator A5046542801 @default.
• W3016250087 creator A5061222063 @default.
• W3016250087 creator A5068055005 @default.
• W3016250087 creator A5071015984 @default.
• W3016250087 creator A5073989429 @default.
• W3016250087 creator A5076696174 @default.
• W3016250087 creator A5079645039 @default.
• W3016250087 creator A5084442967 @default.
• W3016250087 creator A5085131013 @default.
• W3016250087 creator A5088566246 @default.
• W3016250087 date "2020-05-06" @default.
• W3016250087 modified "2023-10-17" @default.
• W3016250087 title "Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha‐fetoprotein after sorafenib in REACH and REACH‐2" @default.
• W3016250087 cites W1828082159 @default.
• W3016250087 cites W1998483833 @default.
• W3016250087 cites W2088464819 @default.
• W3016250087 cites W2162392094 @default.
• W3016250087 cites W2277004004 @default.
• W3016250087 cites W2433097314 @default.
• W3016250087 cites W2560499218 @default.
• W3016250087 cites W2753841357 @default.
• W3016250087 cites W2760537305 @default.
• W3016250087 cites W2787358630 @default.
• W3016250087 cites W2796067155 @default.
• W3016250087 cites W2809889937 @default.
• W3016250087 cites W2890810711 @default.
• W3016250087 cites W2908573150 @default.
• W3016250087 cites W2945730831 @default.
• W3016250087 cites W2953123736 @default.
• W3016250087 cites W2970100900 @default.
• W3016250087 cites W2977604563 @default.
• W3016250087 cites W2977722669 @default.
• W3016250087 cites W2990602950 @default.
• W3016250087 cites W4242769447 @default.
• W3016250087 doi "https://doi.org/10.1111/liv.14462" @default.
• W3016250087 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32279446" @default.
• W3016250087 hasPublicationYear "2020" @default.
• W3016250087 type Work @default.
• W3016250087 sameAs 3016250087 @default.
• W3016250087 citedByCount "23" @default.
• W3016250087 countsByYear W30162500872020 @default.
• W3016250087 countsByYear W30162500872021 @default.
• W3016250087 countsByYear W30162500872022 @default.
• W3016250087 crossrefType "journal-article" @default.
• W3016250087 hasAuthorship W3016250087A5006848714 @default.
• W3016250087 hasAuthorship W3016250087A5008862276 @default.
• W3016250087 hasAuthorship W3016250087A5009242828 @default.
• W3016250087 hasAuthorship W3016250087A5020551368 @default.
• W3016250087 hasAuthorship W3016250087A5022288769 @default.
• W3016250087 hasAuthorship W3016250087A5022484327 @default.
• W3016250087 hasAuthorship W3016250087A5025634287 @default.
• W3016250087 hasAuthorship W3016250087A5027983969 @default.
• W3016250087 hasAuthorship W3016250087A5032900701 @default.
• W3016250087 hasAuthorship W3016250087A5033735284 @default.
• W3016250087 hasAuthorship W3016250087A5039119608 @default.
• W3016250087 hasAuthorship W3016250087A5041690302 @default.
• W3016250087 hasAuthorship W3016250087A5046542801 @default.
• W3016250087 hasAuthorship W3016250087A5061222063 @default.
• W3016250087 hasAuthorship W3016250087A5068055005 @default.
• W3016250087 hasAuthorship W3016250087A5071015984 @default.
• W3016250087 hasAuthorship W3016250087A5073989429 @default.
• W3016250087 hasAuthorship W3016250087A5076696174 @default.
• W3016250087 hasAuthorship W3016250087A5079645039 @default.
• W3016250087 hasAuthorship W3016250087A5084442967 @default.
• W3016250087 hasAuthorship W3016250087A5085131013 @default.
• W3016250087 hasAuthorship W3016250087A5088566246 @default.
• W3016250087 hasBestOaLocation W30162500871 @default.
• W3016250087 hasConcept C121608353 @default.
• W3016250087 hasConcept C126322002 @default.
• W3016250087 hasConcept C143998085 @default.
• W3016250087 hasConcept C207103383 @default.
• W3016250087 hasConcept C2778019345 @default.
• W3016250087 hasConcept C2778695046 @default.
• W3016250087 hasConcept C2779551604 @default.
• W3016250087 hasConcept C44249647 @default.
• W3016250087 hasConcept C50382708 @default.
• W3016250087 hasConcept C67761136 @default.
• W3016250087 hasConcept C71924100 @default.
• W3016250087 hasConcept C90924648 @default.
• W3016250087 hasConceptScore W3016250087C121608353 @default.
• W3016250087 hasConceptScore W3016250087C126322002 @default.
• W3016250087 hasConceptScore W3016250087C143998085 @default.
• W3016250087 hasConceptScore W3016250087C207103383 @default.
• W3016250087 hasConceptScore W3016250087C2778019345 @default.

• next